- Home
- BEAT vs AADI Comparison
BEAT vs AADI Comparison
Compare BEAT & AADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- AADI
- Stock Information
- Founded
- BEAT 2015
- AADI 2011
- Country
- BEAT United States
- AADI United States
- Employees
- BEAT N/A
- AADI N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- AADI Biotechnology: Pharmaceutical Preparations
- Sector
- BEAT Technology
- AADI Health Care
- Exchange
- BEAT Nasdaq
- AADI Nasdaq
- Market Cap
- BEAT 59.8M
- AADI 50.5M
- IPO Year
- BEAT 2021
- AADI N/A
- Fundamental
- Price
- BEAT $2.22
- AADI $2.15
- Analyst Decision
- BEAT Buy
- AADI Hold
- Analyst Count
- BEAT 1
- AADI 3
- Target Price
- BEAT $8.00
- AADI $1.75
- AVG Volume (30 Days)
- BEAT 78.6K
- AADI 116.7K
- Earning Date
- BEAT 11-12-2024
- AADI 11-06-2024
- Dividend Yield
- BEAT N/A
- AADI N/A
- EPS Growth
- BEAT N/A
- AADI N/A
- EPS
- BEAT N/A
- AADI N/A
- Revenue
- BEAT N/A
- AADI $23,817,000.00
- Revenue This Year
- BEAT N/A
- AADI $4.79
- Revenue Next Year
- BEAT N/A
- AADI $10.72
- P/E Ratio
- BEAT N/A
- AADI N/A
- Revenue Growth
- BEAT N/A
- AADI 10.57
- 52 Week Low
- BEAT $1.06
- AADI $1.21
- 52 Week High
- BEAT $3.39
- AADI $5.70
- Technical
- Relative Strength Index (RSI)
- BEAT 49.47
- AADI 70.67
- Support Level
- BEAT $2.06
- AADI $1.90
- Resistance Level
- BEAT $2.30
- AADI $2.19
- Average True Range (ATR)
- BEAT 0.13
- AADI 0.10
- MACD
- BEAT 0.01
- AADI 0.01
- Stochastic Oscillator
- BEAT 47.76
- AADI 86.89
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.